

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC., TEVA PHARMACEUTICALS
USA, INC., and AKORN INC.¹
Petitioners

v.

SAINT REGIS MOHAWK TRIBE and ALLERGAN, INC.
Patent Owners

Case IPR2016-01127 (8,685,930 B2)
Case IPR2016-01128 (8,629,111 B2)
Case IPR2016-01129 (8,642,556 B2)
Case IPR2016-01130 (8,633,162 B2)
Case IPR2016-01131 (8,648,048 B2)
Case IPR2016-01132 (9,248,191 B2)

**PETITIONER TEVA PHARMACEUTICALS USA, INC.'S
UPDATED MANDATORY NOTICES PURSUANT
TO 37 C.F.R. § 42.8(a)(3)**

¹ Cases IPR2017-00576 and IPR2017-00594, IPR2017-00578 and IPR2017-00596, IPR2017-00579 and IPR2017-00598, IPR2017-00583 and IPR2017-00599, IPR2017-00585 and IPR2017-00600, and IPR2017-00586 and IPR2017-00601, have respectively been joined with the captioned proceedings. The word-for-word identical paper is filed in each proceeding identified in the caption pursuant to the Board's Scheduling Order (Paper 10).

Petitioner Teva Pharmaceuticals USA, Inc. (“Teva”) hereby files these Updated Mandatory Notices Pursuant to 37 C.F.R. § 42.8(a)(3) to update the listing of counsel and service information.

I. LEAD AND BACK-UP COUNSEL

Teva hereby adds Ralph Wilson Powers III (Reg. No. 63,504) as back-up counsel:

Ralph Wilson Powers III, Reg. No. 63,504
tpowers-PTAB@sternekessler.com
STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
1100 New York Avenue, N.W.
Washington, D.C. 20005-3932
Tel.: 202-772-8876
Fax: 202-371-2540.

All previously-listed counsel for Teva remain the same.

II. SERVICE INFORMATION

Teva consents to electronic service by email at the email addresses gspeier@carlsoncaspers.com, mschuman@carlsoncaspers.com, IPRCyclosporine@carlsoncaspers.com, tpowers-PTAB@sternekessler.com, and PTAB@sternekessler.com.

Dated: December 26, 2018

Respectfully submitted,
STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

/ R. Wilson Powers III/

Ralph Wilson Powers III, Reg. No. 63,504
Attorney for Petitioner Teva Pharmaceuticals USA,
Inc.

CERTIFICATE OF SERVICE

The undersigned hereby certifies that the foregoing **PETITIONER TEVA PHARMACEUTICALS USA, INC.’S UPDATED MANDATORY NOTICES PURSUANT TO 37 C.F.R. § 42.8(a)(3)** and Teva Pharmaceuticals USA, Inc.’s Updated Power of Attorney were served electronically via e-mail on December 26, 2018, in their entirety on the following counsel of record for Patent Owners:

Dorothy P. Whelan; Michael Kane; Susan Morrison Colletti; Robert M. Oakes;
Jonathan Singer
FISH & RICHARDSON P.C.
IPR13351-0008IP1@fr.com
IPR13351-0008IP2@fr.com
IPR13351-0008IP3@fr.com
IPR13351-0008IP4@fr.com
IPR13351-0008IP5@fr.com
IPR13351-0008IP6@fr.com
PTABI inbound@fr.com

Alfonso Chan; Joseph DePumpo;
Michael W. Shore;
Christopher L. Evans
SHORE CHAN DEPUMPO LLP
achan@shorechan.com
jdepumpo@shorechan.com
mshore@shorechan.com
cevans@shorechan.com

Marsha K. Schmidt
marsha@mkschmidtlaw.com

And on the counsel for Petitioners as follows:

Steven W. Parmelee; Michael T. Rosato;
Jad A. Mills; Wendy L. Devine;
Douglas H. Carsten
WILSON SONSINI GOODRICH & ROSATI
sparmelee@wsgr.com
mrosato@wsgr.com
jmills@wsgr.com
wdevine@wsgr.com
dcarsten@wsgr.com
Attorneys for Mylan Pharmaceuticals Inc.

Michael Dzwonczyk; Azadeh Kokabi;
Travis Ribar
SUGHRUE MION, PLLC
mdzwonczyk@sughrue.com
akokabi@sughrue.com
tribar@sughrue.com
Attorneys for Akorn Inc.

Gary J. Speier; Mark D. Schuman
CARLSON, CASPERS, VANDENBURGH,
LINDQUIST & SCHUMAN, P.A.
gspeier@carlsoncaspers.com
mschuman@carlsoncaspers.com
IPRCyclosporine@carlsoncaspers.com
Attorneys for Teva Pharmaceuticals
USA, Inc.

Dated: December 26, 2018

Respectfully submitted,
STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

/ R. Wilson Powers III/

Ralph Wilson Powers III, Reg. No. 63,504
Attorney for Petitioner Teva Pharmaceuticals USA,
Inc.